BlackRock
PMCB icon

BlackRock’s PharmaCyte Biotech PMCB Stock Holding History

BlackRock’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1 Hold
1
– – ﹤0.01% 5694
2026
Q1 		$1 Hold
1
– – ﹤0.01% 5681
2025
Q4 		$1 Hold
1
– – ﹤0.01% 5529
2025
Q3 		$1 Buy
+1
New +$1 ﹤0.01% 5447
2025
Q2 		– Sell
-14
Closed -$18 – 5566
2025
Q1 		$18 Buy
+14
New +$23 ﹤0.01% 5406
2024
Q3 		– Sell
-13,346
Closed -$26.2K – 5295
2024
Q2 		$26.2K Sell
13,346
-7,758
-37% -$16.7K ﹤0.01% 4967
2024
Q1 		$50K Sell
21,104
-7,665
-27% -$16.6K ﹤0.01% 4868
2023
Q4 		$62.1K Sell
28,769
-12,944
-31% -$28.1K ﹤0.01% 4924
2023
Q3 		$87.6K Sell
41,713
-1,605
-4% -$4.09K ﹤0.01% 4886
2023
Q2 		$124K Sell
43,318
-393
-0.9% -$1.18K ﹤0.01% 4853
2023
Q1 		$127K Buy
43,711
+31,727
+265% +$93.3K ﹤0.01% 4902
2022
Q4 		$35.1K Buy
11,984
+836
+7% +$2.39K ﹤0.01% 5294
2022
Q3 		$27K Buy
11,148
+2,267
+26% +$5.73K ﹤0.01% 5467
2022
Q2 		$20K Buy
+8,881
New +$19.4K ﹤0.01% 5552

Other funds holding PMCB

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EPM
Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

BlackRock's PMCB Position: Q2 2026 in Review

BlackRock held its PharmaCyte Biotech (PMCB) position steady in Q2 2026 at 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #5694.

BlackRock first reported a position in PMCB in Q2 2022 and has held it in 14 quarters since. The position peaked at $127K in Q1 2023. 19 funds tracked by Wall St. Rank hold PMCB as of Q2 2026.

  • BlackRock held 1 share of PharmaCyte Biotech worth $1 as of Q2 2026.
  • BlackRock left its PharmaCyte Biotech share count unchanged in Q2 2026.
  • PharmaCyte Biotech made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #5694 holding.
  • BlackRock first reported a position in PharmaCyte Biotech in Q2 2022 and has held it in 14 quarters since.
  • BlackRock's PharmaCyte Biotech position peaked at $127K in Q1 2023.
  • 19 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.